Hookipa Pharma is a clinical stage biotech company located in Vienna, Austria, that is developing next-generation immunotherapies for infectious diseases and oncology. The company aims to create best-in-class active immunization therapies using its novel proprietary arenavirus vector platforms. With its TheraT® and Vaxwave® platforms, Hookipa Pharma is paving the way for the future of immune-therapy.
Revolutionizing Active Immunization Therapy
Hookipa Pharma’s TheraT® and Vaxwave® platforms are designed to elicit high neutralizing antibody responses along with necessary levels of T cell responses. These two vector platforms are not impeded by vector-neutralizing antibodies, meaning they can be administered repeatedly to provide even greater immune protection. The level of specific T cells generated by TheraT® is unprecedented in the field and has the potential to transform active immune-therapy in cancers.
Promising Results in Clinical Trials
The company has completed the active phase of a Phase 1 trial of a Vaxwave®-based vaccine against cytomegalovirus (CMV), and the results have been promising. Hookipa Pharma is now finalizing clinical development plans for TheraT® in Human Papilloma Virus (HPV)-related head and neck cancers. The technology’s unique combination of both antibody and T cell responses offers a new approach to treating infectious diseases and cancers.
A Passionate Team of Experts
Hookipa Pharma is led by a passionate team of experts with extensive experience in the biotech industry. The team is committed to developing innovative therapies that will transform the way we treat infectious diseases and cancers. The company’s research and development team includes experts in molecular biology, biochemistry, virology, immunology, and clinical development. Hookipa Pharma’s scientific advisory board consists of renowned researchers and clinicians who are experts in their respective fields.
Hookipa Pharma is revolutionizing the field of immune-therapy through its innovative arenavirus vector platforms. With its novel TheraT® and Vaxwave® platforms, the company is creating best-in-class active immunization therapies for infectious diseases and oncology. With promising results in clinical trials, Hookipa Pharma is well-positioned to become a leader in the field of immunotherapy. The company’s passionate team of experts is committed to developing therapies that will change the lives of patients worldwide.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!